Michaël Lévy
Yuma Advisory

  • A Quantics Technologies Partner, Michaël Lévy plays an active role in product development. He has more than 25 years’ experience in the markets.
  • He has been in charge of the foreign exchange options desks of European banks (Société Générale, Commerzbank and Barclays) in London and New York. In 2001, he became hedge fund manager at Société Générale Asset Management Alternative Investments (SGAM AI). He was in charge of multi-strategy funds and was also exposed to alternative multi-management.
  • In 2009, he co-founded 360 Asset Managers, an asset management firm mainly dedicated to asset management advisers. He built long-only products, contributing his expertise in convertible bonds and derivatives. He was also in charge of multi-management. In each of his positions, he had a strong focus on volatility, correlation and risk unit issues, which are at the heart of Quantify.
  • He currently helps asset management companies and financial advisers develop their business. He thereby shares his expertise in management, allocation and hedging processes.
  • Michaël Lévy is a graduate of Ecole des Mines de Nancy and M.I.T. Sloan School of Management.

Philippe Grandjean
BioNautilus Consulting

  • Philippe Grandjean has a solid and pursuant 25 year record of international operations and business performance in challenging leadership roles and multicultural environments. His experience spans roles such as Commercial Operations Management, Strategic Marketing Director, Business Developement, Corporate Communication and lastly Vice-President Global Business.
  • His expertise covers the complete product life-cycle from strategic definition to successful implementation in different healthcare companies as a top player (Bayer diagnostics), a medium size (bioMerieux) & a biotech (Innogenetics / Fujirebio).
  • In 2009 and throughout 5 years career at Innogenetics/Fujirebio, he served as a member of the Management Committee directly involved in all M&A activities including six due diligence processes, leading the portfolio strategy and global marketing re-organization and integration.
  • He holds a state Pharm.D. degree from Paris Université Paris XI (France).